Shantha gets go-ahead for operational revamp

Sanofi's ($SNY) plan for revamping Shantha Biotech won Indian government approval, clearing the way for it to recapture WHO contracts for its Shan5 vaccine. The health agency barred Shan5 in 2010 after quality-control shortfalls. Report